Jalosome for professional
JALOSOME®
The Complete Solution for Patients Undergoing Chemotherapy and RadiotherapyJALOSOME®
The Complete Solution for PatientsUndergoing Chemotherapy and Radiotherapy
Purpose of the Website
The fact that radiotherapy is a therapeutic tool used in various applications for treating different forms of cancer is well-known in the medical world. However, an important aspect to delve into is the side effects associated with this therapeutic approach, with particular attention to skin injuries known as radiodermatitis.
NEW CASES OF CANCER IN ITALY
READ THE IN-DEPTH INSIGHTS library_books SCARICA L'APPROFONDIMENTOof patients diagnosed with cancer will undergo some form of radiotherapy
Radiodermatitis is a side effect directly linked to radiation exposure and affects
of all oncology patients undergoing this procedure
Sophie Seité, René-Jean Bensadoun, Jean-Michel Mazer
Prevention and treatment of acute and chronic radiodermatitis
Breast Cancer (Dove Med Press) 2017; 9: 551–557. Published online 2017 Nov 2. doi: 10.2147/BCTT.S149752
To date, there are no guidelines to assist clinicians in adequately approaching the prevention and treatment of these injuries, which cause pain, ulceration, swelling, increased risk of infection, and the risk of interrupting radiotherapy, significantly impacting the quality of life and the success of the therapies themselves.
This website offers the opportunity to delve into the subject of radiodermatitis and its treatment through in-depth materials such as scientific presentations, links to reference articles, and interviews with clinicians involved in the process of patient care and management of radiation therapy-induced injuries.”
To date, there are no guidelines to assist clinicians in adequately approaching the prevention (3, 4) and treatment of these injuries, which cause pain, ulceration, swelling, increased risk of infection, and the risk of interrupting radiotherapy, significantly impacting the quality of life and the success of the therapies themselves (5). This website offers the opportunity to delve into the subject of radiodermatitis and its treatment through in-depth materials such as scientific presentations, links to reference articles, and interviews with clinicians involved in the process of patient care and management of radiation therapy-induced injuries.”
Presta G1, Puliatti A2, Bonetti L3, Tolotti A3, Sari D4, Valcarenghi D3. Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report and review. Int Wound J. 2019 Dec;16(6):1433-1439.
Iacovelli NA1, Galaverni M2, Cavallo A3, Naimo S1, Facchinetti N1, Iotti C4, Fallai C1, Orlandi E1.
Future Oncol. 2018 Feb;14(3):291-305. doi: 10.2217/fon-2017-0359. Epub 2017 Nov 20. Prevention and treatment of radiation-induced acute dermatitis in head and neck cancer patients: a systematic review.
Drost L1, Li N1, Vesprini D1, Sangha A1, Lee J1, Leung E1, Rakovitch E1, Yee C1, Chow E2, Ruschin M1.
Clin Breast Cancer. 2018 Oct;18(5):e789-e795. doi: 10.1016/j.clbc.2018.03.008. Epub 2018 Mar 15.
Prospective Study of Breast Radiation Dermatitis.
3. Presta G1, Puliatti A2, Bonetti L3, Tolotti A3, Sari D4, Valcarenghi D3. Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report and review. Int Wound J. 2019 Dec;16(6):1433-1439.
4. Iacovelli NA1, Galaverni M2, Cavallo A3, Naimo S1, Facchinetti N1, Iotti C4, Fallai C1, Orlandi E1.
Future Oncol. 2018 Feb;14(3):291-305. doi: 10.2217/fon-2017-0359. Epub 2017 Nov 20. Prevention and treatment of radiation-induced acute dermatitis in head and neck cancer patients: a systematic review.
5. Drost L1, Li N1, Vesprini D1, Sangha A1, Lee J1, Leung E1, Rakovitch E1, Yee C1, Chow E2, Ruschin M1.
Clin Breast Cancer. 2018 Oct;18(5):e789-e795. doi: 10.1016/j.clbc.2018.03.008. Epub 2018 Mar 15.
Prospective Study of Breast Radiation Dermatitis.
Sign up for In-depth Insights
Sign up
Sign in
Sign up
[wppb-register form_name=”professional-user-registration”]
Sign in
[wppb-login]
In this section, you have the opportunity to delve deeper into the subject through in-depth readings and the words of our experts
Radiation therapy skin lesions: the epidemiological data
Dott. Nicola Alessandro Iacovelli
Radiation therapy skin lesions: the epidemiological data
Dott. Nicola Alessandro Iacovelli
More readings
Prevention and treatment of acute and chronic radiodermatitis
Sophie Seité, René-Jean Bensadoun, Jean-Michel Mazer
Read moreSkin-related Quality of Life among Midwestern US Community-based Women with Breast Cancer Experiencing Radiodermatitis
Laura Curr Beamer, Marcia Grant
Read moreA systematic review of patient-rated measures of radiodermatitis in breast cancer radiotherapy
Julie B. Schnur, Bianca Love, Bari L. Scheckner, Sheryl Green, A. Gabriella Wernicke, Guy H. Montgomery
Read moreProspective Study of Breast Radiation Dermatitis.
Drost L1, Li N1, Vesprini D1, Sangha A1, Lee J1, Leung E1, Rakovitch E1, Yee C1, Chow E2, Ruschin M1.
Read moreEffectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report and review.
Presta G1, Puliatti A2, Bonetti L3, Tolotti A3, Sari D4, Valcarenghi D3.
Read morePrevention and treatment of radiation-induced acute dermatitis in head and neck cancer patients: a systematic review.
Iacovelli NA1, Galaverni M2, Cavallo A3, Naimo S1, Facchinetti N1, Iotti C4, Fallai C1, Orlandi E1
Read moreUsing the Dermatology Life Quality Index to Assess How Breast Radiodermatitis Affects Patients’ Quality of Life
Laura Curr Beamer, Marcia Grant
Read moreAcute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy
Fleta N. Bray, Brian J. Simmons, Aaron H. Wolfson, Keyvan Nouri
Read moreIonizing Radiation: The Good, the Bad, and the Ugly
Julie L. Ryan
Read moreA Qualitative Analysis of Acute Skin Toxicity among Breast Cancer Radiotherapy Patients
Julie B. Schnur, Suzanne C. Ouellette, Terry A. DiLorenzo, Sheryl Green, Guy H. Montgomery
Read more
JALOSOME® Soothing gel
Jalosome® Soothing Gel is a formulated solution designed specifically to address radiation-induced dermatitis across its various stages of manifestation. Welcare’s research has developed a formulation that meets the requirements for being a product suitable for the needs of oncology patients undergoing radiotherapy treatment.
Jalosome: 7 active ingredients
7
Jalosome® Soothing Gel contains 7 active ingredients, each serving a specific function within the product. It can be used preventively to stimulate skin cell reproduction, thus promptly responding to damage caused by radiotherapy treatment. This helps reduce the effects, delay the onset, and mitigate the intensity of induced damage. Its efficacy has been proven even in already manifested lesions, including severe cases
Among the components:
PHOSPHATIDYLCHOLINE
ALLANTOIN
HYALURONIC ACID
ACETYLCARNITINE
PER MAGGIORI INFORMAZIONI
Jalosome® Hydrating cream
Nourishing, hydrating, and maintaining skin elasticity is extremely important to prevent issues that can arise from excessive dryness, such as redness, irritations, and flakiness. For this reason, Welcare has decided to introduce alongside Jalosome® Soothing Gel a new formulation, Jalosome® Hydrating Cream. The goal is to provide a solution that can help maintain healthy skin
The primary and fundamental difference lies in the cream formulation of Jalosome® Hydrating Cream. The synergistic action of Aloe Barbadensis, vegetable oils, and panthenol (Vitamin B5) is capable of restoring the hydrophilic properties of the stratum corneum, providing hydration and elasticity to the skin.
Jalosome® Hydrating Cream can be used at the end of the radiotherapy treatment period on intact skin, aiming to stimulate cell renewal and maintain hydrated and elastic skin.
It should not be used during radiotherapy treatment because the oily component it contains is not recommended for use during radiotherapy. During the active treatment phase, Jalosome® Soothing Gel should be used, as its composition characteristics address the specific need.”
Jalosome Hydrating Cream comes in a package containing a 100ml bottle with an airless dispensing system
For more information
The project ”Radiation-Induced Lesions: A Challenge to Overcome”
To assist clinicians in finding adequate management and treatment for radiation-induced lesions, Welcare initiated the project ‘Radiation-Induced Lesions: A Challenge to Overcome.’ The first step involved convening a board of experts from various fields affected by the issue, including radiotherapists, oncologists, pain therapists, dermatologists, and neurologists. The aim was to gather around a table to discuss the current situation and explore possibilities to enhance the quality of life for patients affected by these lesions.”
THE BOARD OF EXPERTS
Dott. Vittorio Guardamagna
Pain Therapist at IEO
Dott.ssa Adriana Ciuffreda
Dermatology Specialist at Scientific Society DDI
Prof. Yvan Torrente
Neurologist at Policlinico di Milano
Prof.ssa Paola Sacerdote
Pharmacologist at University of Milan
Dott. Nicola Alessandro Iacovelli
Radiation Oncologist at INT
Uno degli argomenti che sono stati affrontati ed approfonditi, nel corso dei lavori, riguarda l’importanza di un trattamento delle lesioni che consenta di non interrompere il trattamento radioterapico, interruzione che rappresenta un ostacolo nella cura del paziente.
Il dolore rappresenta uno dei più importanti effetti collaterali legati alle radiodermiti, impattando significativamente sulla qualità di vita dei malati e rappresentando una delle principali cause di interruzione del trattamento.
La survey
Le lesioni da radioterapia sono direttamente collegate alla tecnica radioterapica utilizzata, così come alla dose totale e al volume (Fleta et al.). Negli ultimi anni, la ricerca si è impegnata, più che nello sviluppare soluzione terapeutiche per prevenire e trattare le lesioni indotte da radioterapia, nel tentativo di realizzare strumenti che riducessero al massimo gli eventi avversi collegati al trattamento. Questi nuovi macchinari sono in grado di ridurre la formazione di lesioni di grado severo, ma la loro distribuzione sul territorio è fondamentalmente legata alle grandi strutture.
Qual è la reale situazione nelle oltre 190 radioterapie presenti sul nostro territorio? Di quali strumenti sono dotate? Con che frequenza riscontrano la comparsa di lesioni e con quale gravità? Per rispondere a tutte questi interrogativi, al fine di trovare una soluzione che possa essere d’aiuto a medici e pazienti, in qualunque parte d’Italia si trovino ad operare e dovunque si trovino ad essere curati, Welcare ha lanciato la survey “Radioterapie d’Italia”.
Se sei interessato a partecipare, clicca qui.